Abstract
Inhibition of coagulation factor XII (FXII) activity represents an attractive approach for the treatment and prevention of thrombotic diseases. The few existing FXII inhibitors suffer from low selectivity. Using phage display combined to rational design, we developed a potent inhibitor of FXII with more than 100-fold selectivity over related proteases. The highly selective peptide macrocycle is a promising candidate for the control of FXII activity in antithrombotic therapy and a valuable tool in hematology research.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Drug Discovery*
-
Drug Synergism
-
Factor XII / antagonists & inhibitors*
-
Fibrinolytic Agents / adverse effects*
-
Fibrinolytic Agents / chemical synthesis
-
Fibrinolytic Agents / chemistry
-
Fibrinolytic Agents / pharmacology*
-
Humans
-
Peptides, Cyclic / adverse effects*
-
Peptides, Cyclic / chemical synthesis
-
Peptides, Cyclic / chemistry
-
Peptides, Cyclic / pharmacology*
-
Plasma Kallikrein / antagonists & inhibitors
-
Safety*
Substances
-
Fibrinolytic Agents
-
Peptides, Cyclic
-
Factor XII
-
Plasma Kallikrein